tirzepatide ada improves kidney outcomes in T2DM with increased CV risk Tirzepatide for Obesity Treatment and

Lilly Rx Only NDC 0002-6523-11 Zepbound (tirzepatide) injection 50 mg/2.4 mL (20.8 mg/mL) ATTENTION: Contains 4 doses of 12.5 mg/0.6 mL 2.4 mL MULTI-DOSE VIAL For Subcutaneous Use Needles and Syringes are not included Dispense enclosed Medication Guide to each patient

Semaglutide is a medication approved for type 2 diabetes and has shown weight loss for people with obesity

Avoid use on open wounds or actively inflamed dermatitis unless under clinical supervision

Together, these medications address multiple pathophysiological mechanisms, providing superior glycaemic control and weight management compared to either treatment alone

Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children

Signs You May Be Ready to Switch Medications A plateau in weight loss after 36 months of consistent semaglutide use is the clearest indicator that switching might help